Tradestie Institutional Equity Comparison Engine

SANA vs KALV โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

KALV Overall Edge

KALV Captures Institutional Edge (2โ€“2 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to KalVista Pharmaceuticals, Inc. Common Stock (KALV) driven by superior Valuation, Momentum & Technical while SANA counters with relative strength in Growth & Margin, Options & Structure. Fundamentally, SANA trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus KALV at 25.4x Forward P/E and -57.4% operating margin (+30.7% YoY). In options structure, SANA sits in BREAKDOWN (4th %ile IV; Dealer Gamma Walls on Pro) against KALV sits in UNCLASSIFIED (31st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner KALV
SANA N/M vs KALV 25.4x Fwd P/E
Growth & Margin Winner SANA
Op Margin 0.0% vs -57.4% ยท YoY +0.0% vs +30.7%
Momentum & Technical Winner KALV
1Y -48.6% vs +82.9% ยท 52W Pos 1% vs 100%
Options & Structure Winner SANA
BREAKDOWN (4th %ile IV) vs UNCLASSIFIED (31st %ile IV)
SANA NASDAQ
Sana Biotechnology, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.88
-6.93% 1D
Market Cap $605.3M
1M Return -17.18%
1Y Return -48.63%
Forward P/E N/M
Unified AI Score
44.3 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 66.0 Mom 60.0
KALV NASDAQ
KalVista Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$27.00
+0.04% 1D
Market Cap $1.4B
1M Return +1.09%
1Y Return +82.93%
Forward P/E 25.4x
Unified AI Score
55.1 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 57.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SANA -48.63% KALV +82.93% Spread: +129.21 pp (KALV Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SANA TTM Op. Margin: 0.0% KALV TTM Op. Margin: -57.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SANA vs KALV. Trailing 12-month operating profitability (SANA 0.0% vs KALV -57.4%) and valuation multiples (SANA N/M vs KALV 25.4x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SANA (3) vs KALV (7)
Institutional Metric SANA KALV Criterion Row Winner
Market Capitalization Scale $605.3M $1.4B Larger Scale KALV
Trailing P/E Ratio Valuation N/M 25.4x Lower Multiple KALV
Forward P/E Ratio Valuation N/M 25.4x Lower Multiple KALV
Revenue Growth (YoY) Growth +0.0% +30.7% Higher Growth KALV
Operating Margin (TTM) Profitability 0.0% -57.4% Higher Margin SANA
Net Profit Margin Profitability 0.0% -118.7% Higher Margin SANA
Return on Equity (ROE) Capital Efficiency -79.5% -190.2% Higher ROE SANA
52-Week Range Position Momentum 1% ($2โ€“$5) 100% ($10โ€“$27) Stronger Trend KALV
Beta / 30D Volatility Risk Regime 1.82ฮฒ ยท 78% Vol 0.85ฮฒ ยท 2% Vol Lower Realized Risk KALV
Unified Institutional Score Composite Signal 44.3 / 100 (HOLD) 55.1 / 100 (HOLD) Higher Composite KALV

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SANA vs KALV Buy Guide
SANA BREAKDOWN
57d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 4th %ile
IV Regime Compressed (<25th %ile)
Live SANA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
KALV UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 31st %ile
IV Regime Balanced (25thโ€“60th %ile)
Live KALV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SANA nor KALV registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.